Larimar Therapeutics(LRMR) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results • Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well as available clinical outcomes observations from patients with Friedreich's ataxia (FA) receiving 25 mg of nomlabofusp daily for 30-180 days in ongoing open label extension (OLE) study • Initiation of PK run-in study in adolescents on track by year-end 2024 • Initiation of global confirmato ...